Browsing by Author "Zetti Zainol Rashid"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Community-acquired Methicillin-resistant Staphylococcus Aureus In A Malaysian Tertiary Centre(BioMed Central, 2013) ;Zetti Zainol Rashid ;Norazlah Bahari ;Amizah Othman ;Roslinda Jaafar ;Nurul Azmawati Binti Mohamed @ Abd Aziz ;Idimaz Jabbari ;Anita Sulong ;Rohaidah HashimNorazah AhmadCommunity-acquired methicillin-resistant Staphylococcus aureus (CAMRSA) is a pathogen recognized to be distinct in both phenotype and genotype from hospital-acquired MRSA. We have identified CA-MRSA cases in Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia, including their antibiotic susceptibility patterns and genotypic characteristics. Cases were identified during January to December 2009 from routine clinical specimens, where culture and antibiotic susceptibility results yielded pauci-resistant MRSA isolates suspected as being CA-MRSA. The patients clinical data were collected and their specimens were sent for molecular confirmation and analysis. Five cases of CAMRSA were identified, which had a multi-sensitive pattern on antibiotic susceptibility tests and were resistant to only penicillin and oxacillin. All cases were skin and soft-tissue infections, including diabetic foot with gangrene, infected scalp hematoma, philtrum abscess in a healthcare worker, thrombophlebitis complicated with abscess and infected bedsore. All five cases were confirmed MRSA by detection of mecA. SCCmec typing (ccr and mec complex) revealed SCCmec type IV for all cases except the infected bedsore case. Panton-Valentine leukocidin gene was positive in all isolates. As clinical features among methicillin-sensitive Staphylococcus aureus, CA-MRSA and nosocomial CA-MRSA are indistinct, early recognition is necessary in order to initiate appropriate antibiotics and infection control measures. Continual surveillance of pauci-resistant MRSA and molecular analysis are necessary in order to identify emerging strains as well as their epidemiology and transmission, both in the community and in healthcare setting. - Some of the metrics are blocked by yourconsent settings
Publication Early Viral Clearance Among Covid-19 Patients When Gargling With Povidone-iodine And Essential Oils: A Clinical Trial(Japan Health Sciences University, 2020) ;Nurul Azmawati Mohamed ;Nizam Baharom ;Wan Shahida Wan Sulaiman ;Zetti Zainol Rashid ;Wong Kon Ken ;Umi Kalsom Ali ;Siti Norlia Othman ;Muttaqillah Najihan Samat ;Najma Kori ;Petrick Periyasamy ;Nor Azizan Zakaria ;Agni Nhirmal Kumar Sugurmar ;Nur Ezzaty Mohammad Kazmin ;Cheong Xiong Khee ;Siti Mariyam SanimanIlina IsahakBackground: Gargling had been reported to have significant roles in the prevention and treatment of respiratory tract infections. The purpose of this study was to assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx. Methodology: This pilot, open labeled, randomized, parallel study compared the effect of 30 seconds, 3 times/day gargling using 1% povidone-iodine (PVP-I), essential oils and tap water on SARS-CoV-2 viral clearance among COVID-19 patients in a tertiary hospital in Kuala Lumpur. Progress was monitored by day 4,6 and 12 PCR (Ct value), gargling and symptoms diary as well as clinical observations. Results: Five confirmed Stage 1 COVID-19 patients were recruited for each arm. The age range was from 22 to 56 years old. The majority were males. Two respondents had co-morbidities, which were asthma and obesity. Viral clearance was achieved at day 6 in 100%, 80%, 20% and 0% for 1% PVP-I, essential oils, tap water and control group respectively. Analysis of 1% PVP-I group versus control group showed significant p-value for comparison of PCR results on Day 4, Day 6 and Day 12. Conclusions: This preliminary study showed that gargling with 1% PVP-I and essential oils show great potential to be part of the treatment and management of Stage 1 COVID-19. Larger studies are required to ascertain the benefit of gargling for different stages of COVID-19 patients. This study was registered in clinicaltrial.gov (NCT04410159).